Systematic review with meta-analysis: Comparison between therapeutic regimens for paediatric chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 1, 2015, Pages 12-19

  El Sherbini, A ^a   Mostafa, S ^b   Ali, E ^a  

^a Tanta Fever Hospital   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT;

ANEMIA; CHRONIC HEPATITIS C; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HAIR LOSS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THYROID DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADOLESCENT; CHILD; COMPARATIVE STUDY; DRUG COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; YOUNG ADULT;

EID: 84930475623     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13221     Document Type: Review

References (40)

1. Manns MP, McHutchison JG, Gordon SC, et al,. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy R, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Suoglu OD, Elkabes B, Sokucu S, Saner G,. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002; 34: 199-206.
4. Jara P, Hierro L, De La Vega A, et al,. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis 2008; 27: 142-8.
5. Schwimmer JB, Balistreri WF,. Transmission, natural history and treatment of hepatitis C virus infection in the pediatric population. Semin Liver Dis 2000; 20: 37-46.
6. Di Ciommo V, Russo P, Rava L, Caprino L,. Interferon α in the treatment of chronic hepatitis C in children: a meta-analysis. J Viral Hepat 2003; 10: 210-4.
7. Mack CL, Gonzalez-Peralta RP, Gupta N, et al,. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838-55.
8. Schwarz KB, Mohan P, Narkewicz MR, et al,. Safety, efficacy and pharmacokinetics of peginterferon α2a (40Kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006; 43: 499-505.
9. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A,. Chronic hepatitis C in childhood: an 18-years experience. Clin Infect Dis 2005; 41: 1431-7.
10. Broide E, Kimchi NA, Scapa E,. Chronic hepatitis C infection in children. Minerva Gastroenterol Dietol 2006; 52: 187-93.
11. Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J,. Treatment of hepatitis C in children: a systematic review. PLoS ONE 2010; 5: e11542.
12. Druyts E, Thorlund K, Wu P, et al,. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus Ribavirin for the treatment of chronic Hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 961-7.
13. Yeung LT, King SM, Roberts EA,. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-9.
14. El Sherbini A, Omar A,. Treatment of HBeAg-positive children with chronic hepatitis B: a systematic review and meta-analysis. Dig Liver Dis 2014; 46: 1103-10.
15. Bortolotti F, Giacchino R, Vajro P, et al,. Recombinant interferon alfa therapy in children with chronic hepatitis C. Hepatology 1995; 22: 1623-7.
16. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A,. Lymphoid interferon alfa treatment in chronic hepatitis C. Arch Dis Child 1996; 74: 152-6.
17. Jonas MM, Ott MJ, Nelson SP, Badizadegan K, Peraz-Atayde AR,. Interferon-alpha treatment of hepatitis C virus infection in children. Pediatr Infect Dis J 1998; 17: 241-6.
18. Pensati P, Iorio R, Botta S, et al,. Low virological response to interferon in children with chronic hepatitis C. J Hepatol 1999; 31: 604-11.
19. Wirth S, Lang T, Gehring S, Gerner P,. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36: 1280-4.
20. Gonzalez-Peralta RP, Kelly DA, Haber B, et al,. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety and pharmacokinetics. Hepatology 2005; 42: 1010-8.
21. Rumbo C, Fawaz RL, Emre SH, et al,. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006; 43: 209-16.
22. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al,. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-8.
23. Wirth S, Pieper-Boustani H, Lang T, et al,. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8.
24. Baker RD, Dee D, Baker SS,. Response to pegylated interferon α-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007; 41: 111-4.
25. Jenke ACW, Moser S, Orth V, Zilbauer M, Gerner P, Wirth S,. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa and ribavirin combination therapy. J Viral Hepat 2009; 16: 853-9.
26. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY,. Pegylated interferon α 2B plus ribavirin in the treatment of HCV genotype 4 Infection. Indian J Pediatr 2009; 76: 895-8.
27. Wirth S, Ribes-Konincks C, Calzado MA, et al,. High sustained virological response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Viral Hepat 2010; 52: 501-7.
28. Sokal ET, Bougois A, Stephenne X, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-31.
29. Al Ali J, Owayed S, Al Qabandi W, Husain K, Hasan F,. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9: 156-60.
30. Pawlowska M, Pilarczyk M, Halota W,. Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16: CR616-21.
31. Rosen I, Kori M, Adiv OE, Yerushalmi B, Zion N, Shaoul R,. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C. World J Gastroenterol 2013; 19: 1098-103.
32. El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, et al,. Safety and efficacy of Hansenula-derived pegylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20: 4681-91.
33. Abdel-Hady M, Bansal S, Davison SM, et al,. Treatment of chronic viral hepatitis C in children and adolescents: UK experience. Arch Dis Child 2014; 99: 505-10.
34. El Sherbini A,. Management of chronic hepatitis C in children: a continuous debate. J Hepatol 2010; 52 (Suppl. 1): S107, Abs 254.
35. Inati A, Taher A, Ghorra S, et al,. Efficacy and tolerability of Peginterferon alpha-2a with or without Ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005; 139: 644-6.
36. Zeuzem S, Berg T, Moeller B, et al,. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
37. Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al,. Peginterferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-31.
38. Aronsohn A, Reau N, Jensen D,. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology 2014; 59: 1688-91.
39. D'Ambrosio R, Aghemo A, Colombo M,. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015; 14: 473-84.
40. Petta S, Craxi A,. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int 2015; 35 (Suppl. 1): 4-10.